SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-016926
Filing Date
2021-03-22
Accepted
2021-03-22 15:43:16
Documents
15
Period of Report
2021-03-22

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea138186-6k_biondvax.htm 6-K 9822
2 CORPORATE PRESENTATION ea138186ex99-1_biondvax.htm EX-99.1 21558
3 GRAPHIC ex99-1_001.jpg GRAPHIC 261497
4 GRAPHIC ex99-1_002.jpg GRAPHIC 417439
5 GRAPHIC ex99-1_003.jpg GRAPHIC 226249
6 GRAPHIC ex99-1_004.jpg GRAPHIC 164541
7 GRAPHIC ex99-1_005.jpg GRAPHIC 217397
8 GRAPHIC ex99-1_006.jpg GRAPHIC 233463
9 GRAPHIC ex99-1_007.jpg GRAPHIC 152013
10 GRAPHIC ex99-1_008.jpg GRAPHIC 228617
11 GRAPHIC ex99-1_009.jpg GRAPHIC 143957
12 GRAPHIC ex99-1_010.jpg GRAPHIC 217947
13 GRAPHIC ex99-1_011.jpg GRAPHIC 253659
14 GRAPHIC ex99-1_012.jpg GRAPHIC 192778
15 GRAPHIC ex99-1_013.jpg GRAPHIC 339986
  Complete submission text file 0001213900-21-016926.txt   4024249
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 21761248
SIC: 2836 Biological Products, (No Diagnostic Substances)